第八版美国癌症联合委员会（AJCC）黑色素瘤分期系统：对黑色素瘤治疗和护理的影响。
The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care.
机构信息
a Department of Surgical Oncology , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
b Melanoma and Skin Center , The University of Texas MD Anderson Cancer Center , Houston , TX , USA.
出版信息
Expert Rev Anticancer Ther. 2018 Aug;18(8):775-784. doi: 10.1080/14737140.2018.1489246.
Abstract
The eighth edition of the American Joint Committee on Cancer (AJCC) melanoma staging system was implemented in the United States on 1 January 2018. Areas covered: This article provides an overview of important changes in the eighth edition AJCC staging system from the seventh edition based on analyses of a large international melanoma database. The clinical implications of these changes for melanoma treatment are also discussed. Expert commentary: A standardized and contemporary cancer staging system that facilitates accurate risk stratification is essential to guide patient treatment. The eighth edition of the AJCC staging system is currently the most widely accepted approach to melanoma staging and classification at initial diagnosis.
摘要
《美国癌症联合委员会（AJCC）第八版黑色素瘤分期系统》于 2018 年 1 月 1 日在美国实施。
涵盖领域
本文基于对大型国际黑色素瘤数据库的分析，概述了第八版 AJCC 分期系统与第七版相比的重要变化。还讨论了这些变化对黑色素瘤治疗的临床意义。
专家评论
一个标准化和现代的癌症分期系统，有助于准确的风险分层，对于指导患者治疗至关重要。第八版 AJCC 分期系统是目前在初始诊断时最广泛接受的黑色素瘤分期和分类方法。
相似文献
1
The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care.
Expert Rev Anticancer Ther. 2018 Aug;18(8):775-784. doi: 10.1080/14737140.2018.1489246.
2
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.
3
Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system.
J Dermatol Sci. 2019 May;94(2):284-289. doi: 10.1016/j.jdermsci.2019.04.003. Epub 2019 Apr 17.
4
Staging and prognosis of cutaneous melanoma.
Surg Oncol Clin N Am. 2011 Jan;20(1):1-17. doi: 10.1016/j.soc.2010.09.007.
5
Validation of the American Joint Committee on Cancer Eighth Edition Staging of Patients With Metastatic Cutaneous Melanoma Treated With Immune Checkpoint Inhibitors.
JAMA Netw Open. 2021 Mar 1;4(3):e210980. doi: 10.1001/jamanetworkopen.2021.0980.
6
Projecting Survival in Papillary Thyroid Cancer: A Comparison of the Seventh and Eighth Editions of the American Joint Commission on Cancer/Union for International Cancer Control Staging Systems in Two Contemporary National Patient Cohorts.
Thyroid. 2017 Nov;27(11):1408-1416. doi: 10.1089/thy.2017.0306. Epub 2017 Oct 5.
7
Evaluation of the eighth American Joint Committee on Cancer staging system for malignant melanoma of the skin.
Future Oncol. 2018 Feb;14(5):471-481. doi: 10.2217/fon-2017-0500. Epub 2018 Jan 11.
8
Staging Melanoma: What's Old and New.
Surg Clin North Am. 2020 Feb;100(1):29-41. doi: 10.1016/j.suc.2019.09.007. Epub 2019 Oct 29.
9
External Validation of AJCC Eighth Edition of Non-small-cell Lung Cancer Staging Among African Americans.
Clin Lung Cancer. 2021 May;22(3):e371-e378. doi: 10.1016/j.cllc.2020.05.030. Epub 2020 Jun 2.
10
Validation of the American Joint Committee on Cancer eighth edition staging system in patients undergoing hepatectomy for hepatocellular carcinoma: a US population-based study.
J Surg Res. 2018 Feb;222:55-68. doi: 10.1016/j.jss.2017.09.044. Epub 2017 Nov 1.
引用本文的文献
1
Utility of [Tc]Tc-tilmanocept, an immunosuppressive macrophage functional imaging agent in melanoma patients receiving checkpoint inhibitor treatment: a feasibility study.
Cancer Immunol Immunother. 2025 Sep 6;74(10):298. doi: 10.1007/s00262-025-04127-8.
2
Recurrence Patterns and Survival Outcomes in Clinical Stage IIB/IIC Melanoma: Can We Stratify Patients for Consideration of Neoadjuvant Immunotherapy?
Ann Surg Oncol. 2025 Sep 4. doi: 10.1245/s10434-025-18263-z.
3
Metastatic Melanoma to the Parotid Gland: A Case Report and Review of Current Diagnostic and Treatment Approaches.
Cureus. 2025 Jul 28;17(7):e88892. doi: 10.7759/cureus.88892. eCollection 2025 Jul.
4
Early-Stage Melanoma Benchmark Dataset.
Cancers (Basel). 2025 Jul 26;17(15):2476. doi: 10.3390/cancers17152476.
5
Synchronous Presentation of Nodular Melanoma and Epithelioid Cell Melanoma: Case Report.
Case Rep Oncol Med. 2025 Jul 15;2025:6396505. doi: 10.1155/crom/6396505. eCollection 2025.
6
Spatial determinants of tumor cell dedifferentiation and plasticity in primary cutaneous melanoma.
bioRxiv. 2025 Jun 24:2025.06.21.660851. doi: 10.1101/2025.06.21.660851.
7
Seborrheic Keratosis-Like Melanoma: Novel Insights Into Clinical, Dermoscopic, and Reflectance Confocal Microscopy Diagnosis of an Atypical Melanoma Variant.
Skin Res Technol. 2025 Jul;31(7):e70206. doi: 10.1111/srt.70206.
8
Direct effects of the small molecule PD‑L1 inhibitor BMS‑202 on A375 melanoma cells: Anti‑tumor activity accompanied by increased mitochondrial function.
Mol Med Rep. 2025 Sep;32(3). doi: 10.3892/mmr.2025.13607. Epub 2025 Jul 11.
9
MelanoDB: A dataset of clinical and molecular features of patients with advanced melanoma treated with MAPK inhibitors.
Sci Data. 2025 Jul 4;12(1):1144. doi: 10.1038/s41597-025-05291-3.
10
Liquid biopsy as a potential tool for diagnosis and clinical monitoring of cutaneous and uveal melanoma.
J Liq Biopsy. 2025 Jun 14;9:100306. doi: 10.1016/j.jlb.2025.100306. eCollection 2025 Sep.
本文引用的文献
1
The Rationale and Emerging Use of Neoadjuvant Immune Checkpoint Blockade for Solid Malignancies.
Ann Surg Oncol. 2018 Jul;25(7):1814-1827. doi: 10.1245/s10434-018-6379-8. Epub 2018 Mar 2.
2
Neoadjuvant therapy in melanoma: the next step?
Lancet Oncol. 2018 Feb;19(2):151-153. doi: 10.1016/S1470-2045(18)30016-0. Epub 2018 Jan 18.
3
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial.
Lancet Oncol. 2018 Feb;19(2):181-193. doi: 10.1016/S1470-2045(18)30015-9. Epub 2018 Jan 18.
4
How to use neoadjuvant medical treatment to maximize surgery in melanoma.
Expert Rev Anticancer Ther. 2018 Feb;18(2):121-130. doi: 10.1080/14737140.2018.1421460. Epub 2018 Jan 3.
5
Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update.
J Clin Oncol. 2018 Feb 1;36(4):399-413. doi: 10.1200/JCO.2017.75.7724. Epub 2017 Dec 12.
6
Neoadjuvant systemic therapy for regionally advanced melanoma.
J Surg Oncol. 2018 May;117(6):1164-1169. doi: 10.1002/jso.24939. Epub 2017 Dec 11.
7
Melanoma staging: Evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual.
CA Cancer J Clin. 2017 Nov;67(6):472-492. doi: 10.3322/caac.21409. Epub 2017 Oct 13.
8
The 2017 complete overhaul of adjuvant therapies for high-risk melanoma and its consequences for staging and management of melanoma patients.
Eur J Cancer. 2017 Nov;86:101-105. doi: 10.1016/j.ejca.2017.09.014. Epub 2017 Sep 29.
9
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma.
N Engl J Med. 2017 Nov 9;377(19):1824-1835. doi: 10.1056/NEJMoa1709030. Epub 2017 Sep 10.
10
Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma.
N Engl J Med. 2017 Nov 9;377(19):1813-1823. doi: 10.1056/NEJMoa1708539. Epub 2017 Sep 10.
Zotero 插件